Patent intelligence · US
US 10399994
Compounds and methods for preventing or treating sensory hair cell death
Compounds and methods for preventing or treating sensory hair cell death
Patent details — US 10399994
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2019
- Expiration
- Aug 29, 2039
- Applicant
- Oricula Therapeutics LLC
- Claims
- 9
- CPC classes
- A61K, A61K31/439, A61K31/46, A61K31/7036
Quick answer
US 10399994 (Compounds and methods for preventing or treating sensory hair cell death) is held by Oricula Therapeutics LLC. Status: granted. Granted Sep 3, 2019. Expires Aug 29, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Oricula Therapeutics LLC
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/439, A61K31/46, A61K31/7036, A61K33/243, A61K45/06
More from Oricula Therapeutics LLC
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 10399994?
US 10399994 (Compounds and methods for preventing or treating sensory hair cell death) is held by Oricula Therapeutics LLC. Status: granted. Granted Sep 3, 2019. Expires Aug 29, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10399994?
Oricula Therapeutics LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 10399994 expire?
Our index shows an expiration date of Aug 29, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.